Other languages Xenetic Biosciences, Inc.

Equities

XBIO

US9840156023

Market Closed - Nasdaq Other stock markets 21:30:01 17/05/2024 BST			5-day change	1st Jan Change
3.608 ^USD	+1.63%		-7.38%	+4.57%

05-09	Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-21	Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09
Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21
CLS Therapeutics Discloses its Views on Xenetic Biosciences	03-18
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of Its DNase-Based Oncology Platform	01-17
Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
Xenetic Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23
Xenetic Biosciences to Implement 1-for-10 Reverse Split	12/05/23
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23
Xenetic Biosciences, The Scripps Research Institute Enter Into Research Collaboration	11/04/23
Xenetic Biosciences, Inc. Announces the Appointment of Jonathan Spicer to its Scientific Advisory Board	16/11/22
Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/11/22
Xenetic Biosciences, Inc. Appoints Allan Tsung, to Its Scientific Advisory Board	04/10/22
Xenetic Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11/08/22
Xenetic Biosciences, VolitionRx to Develop Adoptive Cell Therapies to Treat Cancer	02/08/22
Xenetic Biosciences Signs Manufacturing Deal With Catalent Unit for Cancer Platform	07/07/22
Xenetic Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	12/05/22
Xenetic Biosciences, Inc. Enters into Sublicense Agreement with CLS Therapeutics Ltd	27/04/22
Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22/03/22
Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/11/21
Xenetic Biosciences, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2021	12/08/21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Xenetic Biosciences, Inc.

Equities

XBIO

US9840156023

Other languages

Filters